The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
| Autor: | Yanjing Han, Jianan Yu, Zeran Yang, Guang Chen, Zhiyuan Zhang, Kailan Yang, Ye Cui, Long Jin, Guo-Wen Xiao, Tianhao Su |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Combination therapy medicine.drug_class Pyridines Antineoplastic Agents Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Apatinib Chemoembolization Therapeutic Adverse effect Protein Kinase Inhibitors Aged Retrospective Studies Pharmacology Performance status business.industry Liver Neoplasms Retrospective cohort study Middle Aged medicine.disease Survival Analysis 030104 developmental biology chemistry 030220 oncology & carcinogenesis Hepatocellular carcinoma Molecular Medicine Female Liver cancer business Research Paper |
| Zdroj: | Cancer biologytherapy. 20(3) |
| ISSN: | 1555-8576 |
| Popis: | As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|